HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.90 / 10
Netural
Fund flow is strong (7.8/10) with overall positive inflows except a slight outflow in the Small segment. Analyst coverage is limited: 50% Strong Buy, 50% Neutral, but both analysts have 0% historical win rates and negative past returns, leading to a neutral sentiment.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-19
InstitutionWells Fargo
Times predicted2
Historical Win Rate0.0%
Is money flowing into or out of HALO?
- HALO holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.90/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
